Design and synthesis of some substituted thiazolo[3,2-a]pyrimidine derivatives of potential biological activities  by Abdel Moty, Samia G. et al.
Saudi Pharmaceutical Journal (2016) 24, 119–132King Saud University
Saudi Pharmaceutical Journal
www.ksu.edu.sa
www.sciencedirect.comORIGINAL ARTICLEDesign and synthesis of some substituted
thiazolo[3,2-a]pyrimidine derivatives of potential
biological activities* Corresponding author. Tel.: +20 01227432082; fax: +20 02 88
23332776.
E-mail address: mostafa1705@yahoo.com (M.A. Hussein).
Peer review under responsibility of King Saud University.
Production and hosting by Elsevier
http://dx.doi.org/10.1016/j.jsps.2013.12.016
1319-0164 ª 2013 King Saud University. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Samia G. Abdel Moty a, Mostafa A. Hussein a,*, Salah A. Abdel Aziz b,
Mahrous A. Abou-Salim ca Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt
b Department of Pharmaceutical Medecinal Chemistry, Faculty of Pharmacy, Al Azhar University, Assiut, Egypt
c Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Al Azhar University, Assiut, EgyptReceived 9 October 2013; accepted 14 December 2013
Available online 28 December 2013KEYWORDS
Thiazolopyrimidines;
Synthesis;
Antimicrobial;
Anti-inﬂammatory;
AnalgesicAbstract In continuation to our previous work, thiazolopyrimidines 2a–x were synthesized
through intramolecular cyclization of 2-phenacylthio-dihydropyrimidine hydrobromides 1a–x using
polyphosphoric acid. On the other hand, thiazolo[3,2-a]pyrimidine-3-one 3 was coupled with aryl-
diazonium salts or condensed with isatin to afford compounds 4a–c or 5, respectively. Chemical
structure of the target compounds was substantiated by IR, FT-IR, 1H-, 13C and DEPT-13C
NMR, MS as well as microanalyses. Moreover, the lipophilicity of the target compounds is
expressed as ClogP. The antimicrobial screening of the test compounds 2a–x, 4a–c and 5 revealed
moderate activity in comparison to reference drugs. Compounds 2a–c, 2e, 2o and 2v showed a grad-
ual increase in their anti-inﬂammatory activity reaching its maximum at 5 h compared to indometh-
acin. Furthermore, the analgesic activity of compounds 2a–c, 2e, 2o and 2v revealed a maximum
activity after 5 h of injection compared to aspirin and the LD50 of compounds 2e and 2v was deter-
mined.
ª 2013 King Saud University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Ever since the appearance of bacterial and fungal resistance to-
ward the known chemotherapeutic agent and the amazing dis-
covery of new chemotherapeutic molecule constitute a real
challenge. Consequently, new potent chemotherapeutic agents
are needed, and if possible, with new modes of actions (Sahu
et al., 2008). In addition, microbial infections often produce
pain and inﬂammation. Chemotherapeutic, analgesic and
anti-inﬂammatory drugs are prescribed simultaneously in nor-
mal practice. Consequently, a compound possessing all three
activities is recommended (Sahu et al., 2008). Hence, the treat-
ment of pain continues to be the subject of considerable phar-
maceutical and clinical research (Sahu et al., 2008).
In recent years, thiazolopyrimidines have been of interest
due to their vital role in many biological activities (Viveka
et al., 2012) such as antimicrobial (Ghorab et al., 2000; Sayed
et al., 2006; Sherif et al., 1993; Tozkoparan et al., 1999; You-
ssef and Amin, 2012), anti-inﬂammatory (Dinakaran et al.,
2012; Jeanneau-Nicolle et al., 1992; Sayed et al., 2006; Sherif
et al., 1993; Tozkoparan et al., 1999), analgesic (Tozkoparan
et al., 1999), antioxidant (Youssef and Amin, 2012), insecti-
cides (Sherif et al., 1993), antidepressant (Tozkoparan et al.,
1999), antiviral (Sayed et al., 2006), antitumor (Sayed et al.,
2006; Tozkoparan et al., 1999), and calcium channel blocker
activities (Balkan et al., 1992a, 1996; Jeanneau-Nicolle et al.,
1992; Tozkoparan et al., 1999). Additionally, it was reported
that such a ring system has the ability to inhibit the enzyme
30,50-cyclic AMP phosphodiesterase (Sherif et al., 1993), to
have a theophylline-like activity (Sherif et al., 1993) and to
be active against virulent Lewis lung tumor in mice (Sherif
et al., 1993).
In our previous work, a series of ethyl 6-methyl-4-(substi-
tuted)phenyl-2-(substituted)-phenacylthio-1,4-dihydropyrimi-
dine-5-carboxylate hydrobromide 1a–x have been synthesized
and evaluated for their antibacterial and antifungal activities
(Hussein et al., 2011).
Enlightened by aforementioned data and in continuation to
our previous work, we herein the synthesis of some new thiaz-
olo[3,2-a]pyrimidine derivatives for the evaluation of theirN
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Scheme 1 Synthetic route for compounds 2a–x.antimicrobial, anti-inﬂammatory and analgesic effects, if any.
This work is concerned with the study of the effect of struc-
tural modiﬁcation on the biological activities of the target
compounds.
2. Results and discussion
2.1. Chemistry
Compounds 1a–x were cyclodehydrated into the correspond-
ing thiazolo[3,2-a]pyrimidine compounds 2a–x by heating with
freshly prepared polyphosphoric acid (PPA) for 2 h followed
by neutralization with ammonia, Scheme 1.
Basically, such products of 2a–x had been formulated as the
5H-thiazolo [3,2-a] pyrimidine structure A based on the com-
parison of 1H NMR spectral data for both compounds 1a–x
and 2a–x (Balkan et al., 1992b; Sherif et al., 1993); Fig. 1.
1H NMR spectrum of compound 1b (Hussein et al., 2011),
Fig. 2, show the C6-CH3 as singlet signal at d 2.56 ppm and
C4-H as singlet signal at d 5.58 ppm. 1HNMRspectrum of com-
pound 2b as an example, Fig. 2, showed a singlet signal (3H) at d
2.50 ppm assigned for the C7-CH3 protons and singlet signal
(1H) at d 6.13 ppmassigned for the pyrimidineH-5. The appear-
ance of the CH3 protons signal at the same position on both 1b
and 2b and the down ﬁeld shift for the pyrimidine H-5 in 2b, at d
6.13 ppmcompared to the pyrimidineH-4 in 1b, which appeared
at d 5.58 ppm, indicates that the environment around carbon-5
in 2b differs from that around carbon-4 in 1b. Consequently,
we have assigned structure A, Fig. 1, for the reaction products
2a–x (Balkan et al., 1992b; Sherif et al., 1993).
Structures of the synthesized compounds 2a–x were veriﬁed
by IR, 1H-, 13C and DEPT-13C NMR, mass spectra as well as
elemental microanalyses. IR spectra of compounds 2a–x
showed strong absorption bands at 1680–1636 cm1 for car-
bonyl groups of the ester and at 1589–1561 cm1 indicating
C‚N stretching vibration. 1H NMR spectra revealed a triplet
(3H) of quartet (2H) at d 1.12–1.20 and 4.00–4.13 ppm, respec-
tively of the ethyl group and multiplet at d 6.30–8.40 ppm indi-
cating aromatic protons. On the other hand, 13C NMR
spectrum of compound 2k showed a signal at d 14.26 ppmN
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(a) polyphosphoric acid, 110 C, (b) NH4OH.
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Figure 1 Structure of compound A.
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Figure 2 Structure of compounds 1b and 2b.
122 S.G. Abdel Moty et al.corresponding to CH3 of the ethyl group, d 57.16 ppm corre-
sponding to CH2 of the ethyl group, d 166.43 ppm indicating
C-8a and d 166.61 ppm attributed to the carbonyl group.
Moreover, DEPT 13C NMR spectrum of compound 2k
showed inversion of CH2 of the ethyl group and disappearance
of all quaternary carbons while the CH3 and CH groups stay
the same. Moreover, mass spectra (EI) of compounds 2b, 2d,
2e, 2i, 2j, 2n, 2o, 2q and 2u revealed the molecular ion peaks
(M+) corresponding to their molecular weights and M++2
for compounds 2j, 2n, 2o, 2q and 2u. Physicochemical andN
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O
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O
N
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EtO
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(c)
Scheme 2 Synthetic route for compounds 4a–c and 5. (a) bromoace
nitrite, conc. HCl, 0–5 C.spectral data of compounds 2a–x are shown in the experimen-
tal section.
The active methylene carbon atom in compound 3 (Sherif
et al., 1993; Shiryaev et al., 2013) was coupled readily with
equimolar amount of freshly prepared aryldiazonium salt to
give the corresponding 2-arylhydrazono derivatives, com-
pounds 4a–c. The spectroscopic properties of these products
suggest their existence, to a signiﬁcant extent, in the tautomeric
azo forms; hydrazono and diazenyl isomers in 90:10%,
respectively. The hydazono isomer is the major one due to sta-
bilization through the formation of intramolecular hydrogen
bonding, while the presence of diazenyl isomer was proved
by the existence of highly deshielded (C2-H) in accordance
with the reported data (Rida et al., 1986; Weisberger and Tay-
lor, 1981), Scheme 2.
Structures of the synthesized compounds 4a–c were veriﬁed
by IR, 1H-, 13C and DEPT-13C NMR, mass spectra in addition
to elemental microanalyses. IR spectra of compounds 4a–c
showed NH at 3145–3220 cm1, the ester carbonyl group at
1711–1717 cm1 and the carbonyl at position 3 at 1693–
1695 cm1. 1H NMR spectra for compounds 4a–c were char-
acterized by the appearance of singlet signal at d 8.13–
8.83 ppm corresponding to NH proton (exchangeable with
D2O) for hydazono isomer. The most characteristic signals
indicated the presence of the possible two isomeric forms were
the signals for CH3 and CH2 of the ethyl group that appeared
as two sets of triplet at d 1.00–1.40 ppm and two sets of quartet
at d 3.50–4.40 ppm, respectively. On the other hand, 13C NMR
spectrum, of compound 4c revealed the presence of two ethyl
CH3 of the two isomers at d 13.98 and 18.34 ppm, benzylic
carbon at d 20.69 ppm, 7-CH3 at d 22.55 ppm, C-5 at d
55.25 ppm, two ethyl CH2 of the two isomers at d 58.44 and
60.63 ppm, C-6 at d 109.69 ppm, C-2 of diazenyl isomer at d
114.50 ppm, aromatic carbons at d 120.69–139.54 ppm, C-7NH
O
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N
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4a: R=H
4b: R=Cl
4c: R=CH3
tic acid, (b) isatin, sod. acetate, (c) p-(un)substituted-aniline, sod.
Design and synthesis of some substituted thiazolo[3,2-a]pyrimidine derivatives of potential biological activities 123at d 139.71 ppm, and C-2 of hydrazono isomer at d 151.77 ppm
(C‚N). It also showed signals at d 153.36, 161.03 and
165.26 ppm corresponding to C-8a, amidic C‚O and ester
C‚O, respectively. Moreover, DEPT 13C NMR spectrum,
of compound 4c was characterized by the presence of two sig-
nals at d 14.00 ppm and d 18.32 ppm corresponding to the two
ethyl CH3 groups of the two isomers and inversion of two sig-
nals at d 58.44 ppm and d 60.63 ppm indicating the presence of
two ethyl CH2 groups for the two isomers. In addition, all qua-
ternary carbons disappeared while the signals of CH3 and CH
stay the same. Furthermore, mass spectra (EI) of compounds
4b and 4c revealed the molecular ion peaks (M+) correspond-
ing to their molecular weights and M++2 for compound 4c.
Physicochemical and spectral data of compounds 4a–c are
shown in the experimental section.
Structure of compound 5 was veriﬁed by FT-IR, 1H NMR,
mass spectra as well as elemental microanalyses. FT-IR spec-
trum of compound 5 showed characteristic bands at
3200 cm1 indicating the presence of the NH group,
1715 cm1 corresponding to ester C‚O and strong absorption
band at 1697 cm1 corresponding to both amidic C‚O and in-
dole C‚O groups. 1H NMR spectrum showed disappearance
of the active methylene protons of SCH2 signal at d 3.85 ppm
indicating condensation of isatin at C2 of compound 3. It also
showed a multiplet signal at d 6.83–8.96 ppm (9H) indicating
aromatic protons (5 protons of phenyl ring + 4 protons of
indole ring) as well as singlet signal at d 11.16 ppm indicatingTable 1 Antibacterial activity of compounds (2a–x, 4a–c and 5) an
Comp No. S. aureus B. cereus
2a 8 18
2b 8 18
2c 11 17
2d 8 18
2e 13 22
2f – –
2g 16 21
2h – –
2i 10 12
2j – –
2k – –
2l – –
2m 12 12
2n 8 –
2o 11 –
2p – –
2q – –
2r – –
2s 11 17
2t 11 12
2u 10 –
2v – 12
2w 11 15
2x 11 –
4a 8 –
4b 8 –
4c 10 –
5 10 –
CHL 24 30
Control (DMSO) – –
Pi = partial inhibition. – = no inhibition. CHL= chloramphenicol as
Center.the presence of the indole NH group (exchangeable with D2O).
Moreover, mass spectrum (EI) of compound (5) revealed the
molecular ion peak (M+) corresponding to its molecular
weight. Physicochemical and spectral data of compound 5
are cited in the experimental section.
2.1.1. Lipophilicity
The lipophilicity of the target compounds 2a–x, 4a–c and 5 is
expressed in the term of ClogP values (experimental section).
Most of the target compounds exhibited high values for ClogP
are the most active as antimicrobial agents.
2.2. Antimicrobial activities
2.2.1. Antibacterial activity
Results of the antibacterial activity of compounds 2a–x, Ta-
ble 1, revealed that at a concentration of 100 lmol/mL most
of the test compounds were active against most of the used
bacterial strains. Compounds (2f, 2h, 2j–l and 2p–r; with
ClogP from 6.30 to 8.28) were completely inactive against all
used organisms while compound (2v; with ClogP 6.97) was
active only against Bacillus cereus and compound (2x; with
ClogP 6.80) was active only against Staphylococcus aureus.
In addition, compounds 2a–x showed 33.3–66.7% antibac-
terial activity of that of chloramphenicol against S. aureus,
40.0–73.33% against B. cereus, 40.0–52.0% against Escherichiad chloramphenicol (inhibition zones in mm at 100 lmol/mL).
E. coli P. aeruginosa S. marcescens
– – –
– – –
10 13 12
– – –
13 13 16
– – –
13 18 18
– – –
13 – –
– – –
– – –
– – –
12 – 16 pi
12 13 –
11 – –
– – –
– – –
– – –
10 14 –
10 10 12
10 10 –
– – –
10 – –
– – –
8 – –
8 – –
8 – –
– –
25 15 34
– – –
antibacterial standard. AUMC=Assiut University Mycological
124 S.G. Abdel Moty et al.coli, 66.7–120.0% against Pseudomonas aeruginosa and 33.3–
52.3% against Serratia marcescens. Moreover, the variation
of the antibacterial activity with concentrations (MICs) is
showed in Table 3. It was noted that, the most sensitive organ-
isms to the test compounds were B. cereus and P. aeruginosa.
Again, from Tables 1 and 3, compounds (2c, 2e, 2g and 2t;
with ClogP 7.27, 7.05, 7.42 and 7.92, respectively) have a wide
spectrum of the antibacterial activity as being able to inhibit all
test bacterial organisms with MICs ranging from 50 to
3.125 lmol/mL. Compounds (2m and 2s; with ClogP 7.27
and 7.05, respectively) were effective against four out of ﬁve
bacterial strains with MICs ranging from 100 to 25 lmol/mL.
A previous work that deals with design, synthesis and anti-
microbial activity of the new S-phenacylated dihydrpyrimidine
hydrobromide compounds (1a–x) was reported. Thiazolopyr-
imidines 2a–x were synthesized and tested for their antibacte-
rial activity. The results indicated that, the cyclized compounds
(2a–e, 2g, 2m and 2s–w; with ClogP from 6.47 to 7.92) showed
an improvement in the antibacterial activity than the open
analogs.
Moreover, the results of the antibacterial activity of com-
pounds 4a–c and 5, Table 1 indicated that at a concentration
of 100 lmol/mL the test compounds 4a–c were active against
S. aureus and E. coli while compound 5 was active only against
S. aureus. Compounds (4a–c and 5; with ClogP from 4.95 to
5.66) were completely inactive against B. cereus, P. aeruginosa
and S. marcescens.Table 2 Antifungal activity of compounds (2a–x, 4a–c and 5) and
Comp No. C. albicans G. candidum F. ox
2a 13 14 13
2b – – –
2c 15 15 22
2d 13 16 13
2e 14 19 22
2f 11 – –
2g 14 15 18
2h 12 8 15
2i – 10 10
2j – – –
2k 8 – –
2l – – –
2m 14 14 16
2n - 13 12
2o 13 14 pi 10
2p – – –
2q – – –
2r – – –
2s 10 16 13
2t 14 17 23
2u 8 14 18
2v – – –
2w 13 14 14
2x 8 – –
4a – – –
4b – – –
4c – – –
5 – – –
CLO 24 24 25
Control (DMSO) – – –
Pi = partial inhibition. - = no inhibition. CLO= clotrimazole antifunga2.2.2. Antifungal activity
Results of the antifungal activity of compounds 2a–x, Table 2,
indicated that at a concentration of 100 lmol/mL most of the
test compounds were active against most of the used bacterial
strains. Compounds (2b, 2j, 2l, 2p–r and 2v; with ClogP from
6.97 to 7.42) were completely inactive against all used organ-
isms while compounds (2f, 2k and 2x; with ClogP 6.30, 7.92
and 6.80, respectively) were active only against Candida albi-
cans. Compound (2c; with ClogP 7.27) possessed antifungal
activity equal to that of the reference drug against Scopulariop-
sis brevicaulis while compound (2t; with ClogP 7.92) exceeded
that of the reference drug against S. brevicaulis. In addition,
the active compounds 2a–x showed 33.3–62.5% antifungal
activity of that of Clotrimazole against C. albicans with MICs
ranged from 12.5–100 lmol/mL, 33.3–79.2% against Geotri-
chum candidum with MICs ranged from 3.125 to 100 lmol/
mL, 40.0% to 92.0% against Fusarium oxysporum with MICs
ranged from 3.125 to 100 lmol/mL, 28.6% to 50.0% against
Aspergillus ﬂavus with MICs at 100 lmol/mL, 41.7–75.0%
against Trichophyton rubrum with MICs ranged from 3.125
to 100 lmol/mL and 46.2 to 123.1 against S. brevicaulis with
MICs ranged from 25 to 100 lmol/mL.
Moreover, the results indicated that compounds (2a, 2c, 2e,
2g, 2m and 2t; with ClogP 6.55, 7.27, 7.05, 7.42, 7.27 and 7.92,
respectively) have a wide spectrum of antifungal activity being
able to inhibit all test fungal organisms with MICs ranging
from 100 to 3.125 lmol/mL. Compounds (2d, 2h, 2s, 2u andclotrimazole (inhibition zones in mm at 100 lmol/mL).
ysporum A. ﬂavus T. rubrum S. brevicaulis
8 18 12
– – –
12 22 26
– 22 15
13 27 16
– – –
14 25 22
– 16 18
– 16 p.i 22
– – –
– – –
– – –
12 16 20
– – 14
– – 15
– – –
– – –
– – –
– 18 16
13 22 32
– 16 pi 16
– – –
– 15 16
– – –
– – –
– – –
– – –
– – –
28 36 26
– – –
l standard. AUMC=Assiut University Mycological Center.
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were effective against ﬁve out of six fungal strains with MICs
ranging from 100 to 3.125 lmol/mL, Table 4.
Also, in continuation to our previous work (Hussein et al.,
2011), thiazolopyrimidines 2a–x were synthesized and tested
for their antifungal activity. The results revealed that, the cy-
clized compounds (2a, 2c–e, 2g, 2h, 2m, 2o, 2s–u and 2w; with
ClogP from 6.47 to 8.28) showed an improvement in the anti-
fungal activity than the open analogs.
On the other hand, the results of the antifungal activity of
compounds (4a–c and 5; with ClogP from 4.95 to 5.66), indi-
cated that at a concentration of 100 lmol/mL all the com-
pounds were completely inactive against all the test
microorganisms.
It is noteworthy to mention that, within each series, an
increase in the ClogP values is accompanied by an increase
in the antimicrobial activity. The most active compounds
comprise in their structures an electron withdrawing group
(R1 = halogen; R2 = halogen) while the least active com-
pounds comprise in their structures an electron donating group
(R1 = H, CH3; R2 = OCH3, CH3).
2.3. Pharmacological screening
2.3.1. Anti-inﬂammatory activity
The most active compounds 2a–e, 2o and 2t–x as antimicrobial
agents were selected for the evaluation of their in vivo anti-
inﬂammatory effects.
The results of anti-inﬂammatory activity (Table 5),
revealed that all the test compounds showed a gradual
increase of anti-inﬂammatory activity up to its maximum at
5 h ranging from 73.72:97.58% with compounds 2a–c and
2v being the most active giving 92.86:97.58% of that of
indomethacin.
It is noteworthy to mention that, the result of anti-inﬂam-
matory activity indicates that most of the compounds that
showed the highest anti-inﬂammatory activity having in their
structure R = p-Cl–C4H4 or p-OCH3C6H4 moieties indicate
the crucial role of halogen or the OCH3 in the anti-inﬂamma-
tory activity. These results comply with the previously reported
ﬁndings of Kalgutkar et al. (2000).
2.3.2. Analgesic activity
The most active compounds 2a–c, 2e, 2o and 2v with regards to
their anti-inﬂammatory activity were selected for testing their
analgesic activity in mice using the hot plate method (Janssen
and Jageneau, 1957) in comparison to aspirin as a reference
drug.
Results of the analgesic activity (Table 6), revealed that
compounds 2e and 2v showed a gradual increase of analgesic
activity up to its maximum after 5 h of injection with
84.04% and 82.26% of that of aspirin respectively, whereas
the maximum activity of compound 2o appears after 4 h of
injection with 62.64% of the aspirin activity. On the other
hand, compounds 2a and 2b revealed the maximum activity
at 3 h interval with 35.36% and 37.80% of that of aspirin,
respectively while compound 2c was the least active giving
34.39% of aspirin at 5 h interval.
The previous ﬁnding of analgesic activity indicates com-
pounds with the highest analgesic activity having R = p-Cl–
C4H4, p-OCH3C6H4 or p-CH3C6H4 moieties.2.3.3. Acute toxicity (LD50)
The most active compounds 2e and 2v with regards to their
anti-inﬂammatory and analgesic activity were selected for test-
ing their acute toxicity using aspirin as a reference drug.
The median lethal dose (LD50) of compounds 2e and 2v was
determined in mice according to a reported method (Sztarics-
kai et al., 1999) and was found to be nontoxic up to
>1 g/kg whereas the LD50 of aspirin equals to 533 mg/kg
(i.p.) (Abdel-Alem et al., 1980).
3. Conclusion
This work was devoted for the syntheses of some new thiaz-
olo[3,2-a]pyrimidine derivatives 2a–x, 4a–c and 5. The struc-
tures of the target compounds were conﬁrmed. The target
compounds were tested for their antimicrobial activity and
the most active compounds were screened for their MICs.
They showed moderate activity against most of the used
bacterial and fungal strains. Moreover, the lipophilicity of
the target compounds is expressed as ClogP and the most
active antimicrobial compounds comprise in their structures
an electron withdrawing group (R1 = halogen; R2 = halo-
gen) while the least active compounds comprise in their
structures an electron donating group (R1 = H, CH3;
R2 = OCH3, CH3).
In addition, the most active compounds 2a–c, 2e, 2o and 2v
as antimicrobial were tested for their anti-inﬂammatory effects
and they showed a gradual increase in their anti-inﬂammatory
activity reaching its maximum at 5 h in the carrageenan in-
duced paw edema test. The p-Cl–C4H4 or p-OCH3C6H4 deriv-
atives showed the highest anti-inﬂammatory activity, which
indicate the crucial role of halogen or OCH3 groups.
Furthermore, the most active compounds 2a–c, 2e, 2o and
2v with regards to their anti-inﬂammatory activity were
selected for testing their analgesic activity. The tested com-
pounds (2e and 2v) showed a gradual increase in their analgesic
activity up to its maximum after 5 h of injection. In addition,
the LD50 of them was determined in mice and was found
nontoxic up to >1 g/kg whereas the LD50 of aspirin is
533 mg/kg (i.p.).
4. Experimental
Melting points were determined on an electrothermal melting
point apparatus (Stuart Scientiﬁc, Model SMP1, Staffordshire,
UK) and were uncorrected. Monitoring of the chemical reac-
tions was carried out by TLC using precoated silica gel plates
(kieselgel 0.25 mm, 60 G F254, Merk, Darmstadt, Germany)
and CHCl3/CH3COCH3 (9:1 v/v) as the mobile phase. Visual-
ization of the spots was effected by ultraviolet lamp (Spectro-
line Model CM-10, Seattle, USA), at wavelengths 254 and
365 nm and/or iodine stain.
IR and FT-IR spectra were carried out as KBr disks on a
Shimadzu IR-470 spectrometer (Shimadzu, Kyoto, Japan)
and Thermo scientiﬁc 912A0683 spectrometer (Thermo scien-
tiﬁc, Japan) respectively, at the Faculty of Pharmacy, Assiut
University, Assiut, Egypt. 1H NMR spectra were scanned on
a Varian EM-360L NMR spectrophotometer (60 MHz, Var-
ian, CA, USA) at the Faculty of Pharmacy, Assiut University.
1H, 13C and DEPT 13C NMR spectra were scanned on
JEOLJNM-LA series FT-NMR system (400 MHz, JEOL,
126 S.G. Abdel Moty et al.Tokyo, Japan) at the Assiut University Unit of Trace Analysis,
Assiut University, Assiut, Egypt. Chemical shifts are expressed
in d-values (ppm) relative to tetramethylsilane (TMS) as an
internal standard, using CDCl3 or DMSOd6 as solvents, and
deuterium oxide was used for the detection of the exchange-
able protons.
Mass spectra were recorded on a JMS-600H mssroute mass
spectrometer (JEOL, Tokyo, Japan) at the Assiut University
Unit of Trace Analysis, Assiut University, Assiut, Egypt and
on Gas chromatography Mass, Quadrable-2010 Plus (Shima-
dzo, Kyoto, Japan) at the Micro Analytical Center, Faculty
of Science, Cairo University, Cairo, Egypt.
Elemental microanalyses were performed on a Vario EL-
CHNS Elemental Analyzer (Elementary Analysis GmbH, Ger-
many), at Assiut University Unit of Trace Analysis, Assiut
University, Assiut, Egypt and on a Vario elemental analyzer
III (Vario, Hanau, Germany) at the Micro Analytical Center,
Faculty of Science, Cairo University, Cairo, Egypt.
4.1. Calculations of logarithm partition coefﬁcient values
(ClogP)
The logP values of the target compounds 2a–x, 4a–c and 5,
were computed with a routine method called the calculated
logP (ClogP) contained in a PC-software package (McLogP
2.0, BioByte Corp., CA, USA). A representation of the molec-
ular structure where the hydrogens were omitted or ‘‘sup-
pressed’’ (SMILES notation) entered into the program,
which computes the logP bases on Crippen’s fragmentation
(Leo, 1993).
Most of chemicals used were of commercial grade: Aniline,
anhydrous sodium acetate (El Nasr Pharm. Co. Egypt), p-
chloroaniline, isatin (Aldrich, Germany), bromoacetic acid
and p-methyl aniline (Fluka, Germany). All other chemicals
and solvents are of the reagent grade.
4.2. General method for synthesis of ethyl 3,5-di(substituted)
phenyl-7-methyl-5H-thiazolo[3,2-a]pyrimidine-6-carboxylate,
2a–x
The appropriate compound, 1a–x, was heated at 110–120 C
for 2 h with 10–15 times their weight of freshly prepared
polyphosphoric acid (Dennler and Frasca, 1966). The
reaction mixture was cooled, poured with stirring into ice-
water, neutralized with concentrated ammonia and stirred
overnight until crystallization was complete. The separated
solid product was ﬁltered, washed with water, dried and crys-
tallized from hexane except compounds 2h, 2i, 2n, 2q, 2w that
were crystallized from ethyl acetate–hexane mixture (2:1),
Scheme 1.
4.2.1. Ethyl 3-(4-bromophenyl)-7-methyl-5-phenyl-5H-thiazolo
[3,2-a]pyrimidine-6-carboxylate, 2b
m.p. 154–155 C; yield 83%;Rf. 0.28 (CHCl3:CH3COCH3 9:1);
ClogP 7.42; IR (KBr) t (cm1): 1676 (C‚O), 1560 (C‚N); 1H
NMR (CDCl3): (ppm) 1.15 (3H, t, CH2CH3), 2.50 (3H, s,
CH3), 4.06 (2H, q, CH2CH3), 6.13 (2H, s, pyr. H-5, thia H-
2), 6.53–7.56 (9H, m, Ar–H); EI-MS m/z (%) 455 (M+, 26).
Anal. Calcd (%) for C22H19BrN2O2S: C, 58.03; H, 4.21; N,
6.15. Found, C, 58.00; H, 4.19; N, 6.06.4.2.2. Ethyl 3-(4-methoxyphenyl)-7-methyl-5-phenyl-5H-
thiazolo[3,2-a]pyrimidine-6-carboxylate, 2d
m.p. 135–137 C; yield 88%; Rf. 0.58 (CHCl3:CH3COCH3
9:1); ClogP 6.47; IR (KBr) t (cm1): 1661 (C‚O), 1574
(C‚N); 1H NMR (CDCl3): (ppm) 1.15 (3H, t, CH2CH3),
2.50 (3H, s, CH3), 4.06 (2H, q, CH2CH3), 6.13 (2H, s, pyr.
H-5, thia H-2), 6.53–7.56 (9H, m, Ar–H); EI-MS m/z (%)
406 (M+, 51.82), 407 (M++1, 50), 408 (M++2, 49). Anal.
Calcd (%) for C23H22N2O3S: C, 67.96; H, 5.46; N, 6.89.
Found, C, 67.83; H, 5.47; N, 6.83.
4.2.3. Ethyl 7-methyl-3-(4-methylphenyl)-5-phenyl-5H-
thiazolo[3,2-a]pyrimidine-6-carboxylate, 2e
m.p. 110–112 C; yield 89%; Rf. 0.28 (CHCl3:CH3COCH3
9:1); ClogP 7.05; IR (KBr) t (cm1): 1679 (C‚O), 1564
(C‚N); 1H NMR (CDCl3): (ppm) 1.21 (3H, t, CH2CH3),
2.47 (3H, s, –C6H4–CH3), 2.58 (3H, s, CH3), 4.12 (2H, q, CH2-
CH3), 6.18 (1H, s, pyr. H-5), 6.24 (1H, s, thia H-2), 6.69–7.66
(9H, m, Ar–H); EI-MS: m/z (%) 390 (M+, 23), 391 (M++1,
6), 392 (M++2, 2). Anal. Calcd (%) for C23H22N2O2S: C,
70.74; H, 5.68; N, 7.17. Found, C, 70.63; H, 5.59; N, 7.26.
4.2.4. Ethyl 7-methyl-3-(4-nitrophenyl)-5-phenyl-5H-
thiazolo[3,2-a]pyrimidine-6-carboxylate, 2f
m.p. 142 C; yield 72%; Rf. 0.24 (CHCl3:CH3COCH3 9:1);
ClogP 6.30; IR (KBr) t (cm1): 1678 (C‚O), 1589 (C‚N);
1H NMR (CDCl3): (ppm) 1.15 (3H, t, CH2CH3), 2.40 (3H, s,
CH3), 4.06 (2H, q, CH2CH3), 6.09 (1H, s, pyr. H-5), 6.24
(1H, s, thia H-2), 6.66–8.33 (9H, m, Ar–H). Anal. Calcd (%)
for C22H19N3O4S: C, 62.69; H, 4.54; N, 9.97. Found, C,
62.66; H, 4.75; N, 9.92.
4.2.5. Ethyl 5-(4-bromophenyl)-7-methyl-3-phenyl-5H-
thiazolo[3,2-a]pyrimidine-6-carboxylate, 2g
m.p. 111–113 C; yield 70%; Rf. 0.36 (CHCl3:CH3COCH3
9:1); ClogP 7.42; IR (KBr) t (cm1): 1679 (C‚O), 1570
(C‚N); 1H NMR (CDCl3): d 1.15 (3H, t, CH2CH3), 2.46
(3H, s, CH3), 4.06 (2H, q, CH2CH3), 6.12 (2H, s, pyr. H-5, thia
H-2), 6.40–7.53 (9H, m, Ar–H). Anal. Calcd (%) for C22H19-
BrN2O2S: C, 58.03; H, 4.21; N, 6.15. Found, C, 57.83; H,
4.30; N, 6.06.
4.2.6. Ethyl 3,5-di(4-bromophenyl)-7-methyl-5H-thiazolo[3,2-
a]pyrimidine-6-carboxylate, 2h
m.p. 192–193 C; yield 90%; Rf. 0.36 (CHCl3:CH3COCH3
9:1); ClogP 8.28; IR (KBr) t (cm1): 1678 (C‚O), 1562
(C‚N); 1H NMR (CDCl3): (ppm) 1.12 (3H, t, CH2CH3),
2.46 (3H, s, CH3), 4.00 (2H, q, CH2CH3), 6.00 (1H, s, pyr.
H-5), 6.03 (1H, s, thia H-2), 6.39–7.50 (9H, m, Ar–H). Anal.
Calcd (%) for C22H18Br2N2O2S: C, 49.46; H, 3.40; N, 5.24.
Found, C, 49.63; H, 3.69; N, 5.07.
4.2.7. Ethyl 5-(4-bromophenyl)-3-(4-chlorophenyl)-7-methyl-
5H-thiazolo[3,2-a]pyrimidine-6-carboxylate, 2i
m.p. 185–187 C; yield 85%; Rf. 0.36 (CHCl3:CH3COCH3
9:1); ClogP 8.13; IR (KBr) t (cm1): 1678 (C‚O), 1564
(C‚N); 1H NMR (CDCl3): (ppm) 1.15 (3H, t, CH2CH3),
2.43 (3H, s, CH3), 4.03 (2H, q, CH2CH3), 6.00 (1H, s, pyr.
H-5), 6.15 (1H, s, thia H-2), 6.42–7.50 (8H, m, Ar–H); EI-MS
m/z (%) 489 (M+, 10), 490 (M++1, 0.28). Anal. Calcd (%)
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53.70; H, 3.63; N, 6.02.
4.2.8. Ethyl 5-(4-bromophenyl)-3-(4-methoxyphenyl)-7-
methyl-5H-thiazolo[3,2-a]pyrimidine-6-carboxylate, 2j
m.p. 185–187 C; yield 85%; Rf. 0.32 (CHCl3:CH3COCH3
9:1); ClogP 7.34; IR (KBr) t (cm1): 1679 (C‚O), 1565
(C‚N); 1H NMR (CDCl3): (ppm) 1.15 (3H, t, CH2CH3),
2.40 (3H, s, CH3), 3.81 (3H, s, OCH3), 4.03 (2H, q, CH2CH3),
6.06 (2H, s, pyr. H-5, thia H-2), 6.50–7.30 (8H, m, Ar–H); EI-
MS m/z (%) 485 (M+, 4), 486 (M++1, 18), 487 (M++2, 7).
Anal. Calcd (%) for C23H21BrN2O3S: C, 56.91; H, 4.36; N,
5.77. Found, C, 56.87; H, 4.40; N, 6.10.
4.2.9. Ethyl 5-(4-bromophenyl)-7-methyl-3-(4-methylphenyl)-
5H-thiazolo[3,2-a]pyrimidine-6-carboxylate, 2k
m.p. 183–185 C; yield 88%; Rf. 0.36 (CHCl3:CH3COCH3
9:1); ClogP 7.92; IR (KBr) t (cm1): 1678 (C‚O), 1564
(C‚N); 1H NMR (CDCl3): (ppm) 1.22 (3H, t, CH2CH3),
2.46 (3H, s, –C6H4–CH3), 2.48 (3H, s, CH3), 4.11 (2H, q, CH2-
CH3), 6.18 (2H, s, pyr. H-5, thia H-2), 6.68–7.31 (8H, m, Ar–
H); 13C NMR (CDCl3): (ppm) 14.26 (CH2CH3); 21.37 (–
C6H4–CH3), 23.59 (7-CH3), 57.16 (CH2CH3), 59.77 (C-5),
100.66 (C-6), 102.50 (C-2), 122.02–139.89 (Ar–C + Ar–CH),
141.17 (C-3), 156.05 (C-7), 166.43 (C-8a), 166.61 (CO); DEPT
13C NMR (CDCl3): (ppm) 14.24(CH2CH3), 21.38 (7-CH3),
23.62 (–C6H4–CH3), 57.16 (inverted CH2CH3), 59.77 (C-5),
102.55 (C-2), 128.25–131.25 (Ar–CH). Anal. Calcd (%) for
C23H21BrN2O2S: C, 58.85; H, 4.51; N, 5.97. Found, C,
58.82; H, 4.57; N, 6.33.
4.2.10. Ethyl 5-(4-bromophenyl)-7-methyl-3-(4-nitrophenyl)-
5H-thiazolo[3,2-a]pyrimidine-6-carboxylate, 2l
m.p. 194–195 C; yield 87%; Rf. 0.22 (CHCl3:CH3COCH3
9:1); ClogP 7.16; IR (KBr) t (cm1): 1679 (C‚O), 1564
(C‚N); 1H NMR (CDCl3): (ppm) 1.15 (3H, t, CH2CH3),
2.50 (3H, s, CH3), 4.10 (2H, q, CH2CH3), 6.06 (1H, s, pyr.
H-5), 6.27 (1H, s, thia H-2), 6.50–8.40 (8H, m, Ar–H). Anal.
Calcd (%) for C22H18BrN3O4S: C, 52.81; H, 3.63; N, 8.40.
Found, C, 52.99; H, 3.87; N, 8.02.
4.2.11. Ethyl 5-(4-chlorophenyl)-7-methyl-3-phenyl-5H-
thiazolo[3,2-a]pyrimidine-6-carboxylate, 2m
m.p. 155–156 C; yield 85%; Rf. 0.38 (CHCl3:CH3COCH3
9:1); ClogP 7.27; IR (KBr) t (cm1): 1680 (C‚O), 1563
(C‚N); 1H NMR (CDCl3): (ppm) 1.16 (3H, t, CH2CH3),
2.50 (3H, s, CH3), 4.13 (2H, q, CH2CH3), 6.15 (2H, s, pyr.
H-5, thia H-2), 6.63–7.63 (9H, m, Ar–H). Anal. Calcd (%)
for C22H19ClN2O2S: C, 64.30; H, 4.66; N, 6.82. Found, C,
64.47; H, 4.71; N, 6.60.
4.2.12. Ethyl 3-(4-bromophenyl)-5-(4-chlorophenyl)-7-methyl-
5H-thiazolo[3,2-a]pyrimidine-6-carboxylate, 2n
m.p. 157–158 C; yield 76%; Rf. 0.42 (CHCl3:CH3COCH3
9:1); ClogP 8.13; IR (KBr) t (cm1): 1636 (C‚O), 1562
(C‚N); 1H NMR (CDCl3): (ppm) 1.20 (3H, t, CH2CH3),
2.48 (3H, s, CH3), 4.12 (2H, q, CH2CH3), 6.12 (1H, s, pyr.
H-5), 6.22 (1H, s, thia H-2), 6.66–7.72 (8H, m, Ar–H). EI-
MS m/z (%) 489 (M+, 51), 490 (M++1, 25), 491 (M++2,29). Anal. Calcd (%) for C22H18BrClN2O2S: C, 53.95; H,
3.70; N, 5.72. Found, C, 53.83; H, 3.89; N, 5.59.
4.2.13. Ethyl 3,5-di(4-chlorophenyl)-7-methyl-5H-thiazolo[3,2-
a]pyrimidine-6-carboxylate, 2o
m.p. 154–155 C; yield 91%; Rf. 0.39 (CHCl3:CH3COCH3
9:1); ClogP 7.98; IR (KBr) t (cm1): 1677 (C‚O), 1564
(C‚N); 1H NMR (CDCl3): (ppm) 1.15 (3H, t, CH2CH3),
2.46 (3H, s, CH3), 4.06 (2H, q, CH2CH3), 6.03 (1H, s, pyr.
H-5), 6.12 (1H, s, thia H-2), 6.60–7.48 (8H, m, Ar–H). EI-MS:
m/z (%) 445 (M+, 12), 446 (M++1, 20), 447 (M++2, 5).
Anal. Calcd (%) for C22H18Cl2N2O2S: C, 59.33; H, 4.07; N,
6.29. Found, C, 59.48; H, 4.00; N, 6.30.
4.2.14. Ethyl 5-(4-chlorophenyl)-3-(4-methoxyphenyl)-7-
methyl-5H-thiazolo[3,2-a]pyrimidine-6-carboxylate, 2p
m.p. 154–156 C; yield 75%; Rf. 0.36 (CHCl3:CH3COCH3
9:1); ClogP 7.19; IR (KBr) t (cm1): 1680 (C‚O), 1561
(C‚N); 1H NMR (CDCl3): (ppm) 1.15 (3H, t, CH2CH3),
2.46 (3H, s, CH3), 3.78 (3H, s, OCH3), 4.06 (2H, q, CH2CH3),
6.06 (2H, s, pyr. H-5, thia H-2), 6.50–7.13 (8H, m, Ar–H).
Anal. Calcd (%) for C23H21ClN2O3S: C, 62.65; H, 4.80; N,
6.35. Found, C, 62.42; H, 4.75; N, 6.10.
4.2.15. Ethyl 5-(4-chlorophenyl)-7-methyl-3-(4-methylphenyl)-
5H-thiazolo[3,2-a]pyrimidine-6-carboxylate, 2q
m.p. 100–102 C; yield 80%; Rf. 0.44 (CHCl3:CH3COCH3
9:1); ClogP 7.77; IR (KBr) t (cm1): 1679 (C‚O), 1567
(C‚N); 1H NMR (CDCl3): (ppm) 1.15 (3H, t, CH2CH3),
2.39 (6H, s, 2CH3), 4.06 (2H, q, CH2CH3), 6.15 (1H, s, pyr.
H-5), 6.18 (1H, s, thia H-2), 6.48–7.39 (8H, m, Ar–H). Anal.
Calcd (%) for C23H21ClN2O2S: C, 65.01; H, 4.98; N, 6.59.
Found, C, 65.83; H, 4.91; N, 6.23.
4.2.16. Ethyl 5-(4-chlorophenyl)-7-methyl-3-(4-nitrophenyl)-
5H-thiazolo[3,2-a]pyrimidine-6-carboxylate, 2r
m.p. 120–121 C; yield 92%; Rf. 0.32 (CHCl3:CH3COCH3
9:1); ClogP 7.01; IR (KBr) t (cm1): 1679 (C‚O), 1565
(C‚N); 1H NMR (CDCl3): d 1.20 (3H, t, CH2CH3), 2.46
(3H, s, CH3), 4.13 (2H, q, CH2CH3), 6.13 (1H, s, pyr. H-5),
6.50 (1H, s, thia H-2), 6.60–8.36 (8H, m, Ar–H). Anal. Calcd
(%) for C22H18ClN3O4S: C, 57.96; H, 3.98; N, 9.22. Found,
C, 57.79; H, 4.00; N, 8.79.
4.2.17. Ethyl 7-methyl-5-(4-methylphenyl)-3-phenyl-5H-
thiazolo[3,2-a]pyrimidine-6-carboxylate, 2s
m.p. 150–151 C; yield 88%; Rf. 0.40 (CHCl3:CH3COCH3
9:1); ClogP 7.05; IR (KBr) t (cm1): 1679 (C‚O), 1567
(C‚N); 1H NMR (CDCl3): (ppm) 1.15 (3H, t, CH2CH3),
2.16 (3H, s, C6H5–CH3), 2.46 (3H, s, CH3), 4.00 (2H, q, CH2-
CH3), 6.03 (2H, s, pyr. H-5, thia H-2), 6.39–7.47 (9H, m, Ar–
H). Anal. Calcd (%) for C23H22N2O2S: C, 70.74; H, 5.68; N,
7.17. Found, C, 70.51; H, 6.38; N, 7.08.
4.2.18. Ethyl 3-(4-bromophenyl)-7-methyl-5-(4-methylphenyl)-
5H-thiazolo[3,2-a]pyrimidine-6-carboxylate, 2t
m.p. 174–176 C; yield 79%; Rf. 0.42 (CHCl3:CH3COCH3
9:1); ClogP 7.92; IR (KBr) t (cm1): 1678 (C‚O), 1563
(C‚N); 1H NMR (CDCl3): (ppm) 1.20 (3H, t, CH2CH3),
2.20 (3H, s, –C6H4–CH3), 2.50 (3H, s, CH3), 4.06 (2H, q, CH2-
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(8H, m, Ar–H). Anal. Calcd (%) for C23H21BrN2O2S: C,
58.85; H, 4.51; N, 5.97. Found, C, 58.84; H, 4.57; N, 6.15.
4.2.19. Ethyl 3-(4-chlorophenyl)-7-methyl-5-(4-methylphenyl)-
5H-thiazolo[3,2-a]pyrimidine-6-carboxylate, 2u
m.p. 173–175 C; yield 85%; Rf. 0.39 (CHCl3:CH3COCH3
9:1); ClogP 7.77; IR (KBr) t (cm1): 1677 (C‚O), 1566
(C‚N); 1H NMR (CDCl3): d 1.16 (3H, t, CH2CH3), 2.20
(3H, s, –C6H4–CH3), 2.42 (3H, s, CH3), 4.06 (2H, q, CH2CH3),
6.03 (1H, s, pyr. H-5), 6.10 (1H, s, thia H-2), 6.50–7.50 (8H, m,
Ar–H). EI-MS m/z (%) 424 (M+, 53), 425 (M++1, 20), 426
(M++2, 36). Anal. Calcd (%) for C23H21ClN2O2S: C, 65.01;
H, 4.98; N, 6.59. Found, C, 65.06; H, 5.10; N, 6.61%.
4.2.20. Ethyl 3-(4-methoxyphenyl)-7-methyl-5-(4-
methylphenyl)-5H-thiazolo[3,2-a]pyrimidine-6-carboxylate, 2v
m.p. 162–164 C; yield 89%; Rf. 0.33 (CHCl3:CH3COCH3
9:1); ClogP 6.97; IR (KBr) t (cm1): 1668 (C‚O), 1567
(C‚N); 1H NMR (CDCl3): (ppm) 1.13 (3H, t, CH2CH3),
2.17 (3H, s, –C6H4–CH3), 2.46 (3H, s, CH3), 3.75 (3H, s,
OCH3), 4.00 (2H, q, CH2CH3), 5.94 (1H, s, pyr. H-5), 6.00
(1H, s, thia H-2), 6.42–7.00 (8H, m, Ar–H). Anal. Calcd (%)
for C24H24N2O3S: C, 68.55; H, 5.75; N, 6.66. Found, C,
67.93; H, 6.79; N, 6.49.
4.2.21. Ethyl 7-methyl-3,5-di(4-methylphenyl)-5H-
thiazolo[3,2-a]pyrimidine-6-carboxylate, 2w
m.p. 195–196 C; yield 88%; Rf. 0.39 (CHCl3:CH3COCH3
9:1); ClogP 7.55; IR (KBr) t (cm1): 1680 (C‚O), 1570
(C‚N); 1H NMR (CDCl3): (ppm) 1.16 (3H, t, CH2CH3),
2.20 (3H, s, –C6H4–CH3), 2.50 (6H, s, –C6H4–CH3, CH3),
4.06 (2H, q, CH2CH3), 6.03 (1H, s, pyr. H-5), 6.10 (1H, s, thia
H-2), 6.50–8.00 (8H, m, Ar–H). Anal. Calcd (%) for C24H24-
N2O2S: C, 71.26; H, 5.98; N, 6.93. Found, C, 71.13; H, 5.95;
N, 6.64.
4.2.22. Ethyl 7-methyl-5-(4-methylphenyl)-3-(4-nitrophenyl)-
5H-thiazolo[3,2-a]pyrimidine-6-carboxylate, 2x
m.p. 134–135 C; yield 91%; Rf. 0.33 (CHCl3:CH3COCH3
9:1); ClogP 6.80; IR (KBr) t (cm1): 1652 (C‚O), 1560
(C‚N); 1H NMR (CDCl3): d 1.16 (3H, t, CH2CH3), 2.20
(3H, s, –C6H4–CH3), 2.42 (3H, s, CH3), 4.03 (2H, q, CH2CH3),
6.00 (1H, s, pyr. H-5), 6.23 (1H, s, thia H-2), 6.42–8.31 (8H, m,
Ar–H). Anal. Calcd (%) for C23H21N3O4S: C, 63.43; H, 4.86;
N, 9.65. Found, C, 62.88; H, 5.38; N, 9.51.
4.3. General method for synthesis of ethyl 5-phenyl-2,3-dioxo-2-
(un)substituted phenyl hydrazono-7-methyl-2,3-dihydro-5H-
thiazolo[3,2-a]pyrimidine-6-carboxylate, 4a–c
The appropriate aryldiazonium chloride (10 mmol) was pre-
pared by adding concentrated hydrochloric acid (3 mL) to
the appropriate aromatic amine (10 mmol) at 0–5 C and treat-
ing the resulting hydrochloride solution with a cold solution of
sodium nitrite (0.69 g, 10 mmol; in 5 mL water). Then, it was
added drop wise with constant stirring at 0–5 C to a cold solu-
tion of compound 3 (3.16 gm, 10 mmol,) in an absolute etha-
nol (80 mL), containing sodium acetate (3.02 gm, 37 mmol).
The reaction mixture was stirred at room temperature for2 h then diluted with cold water (30 mL) whereby the resultant
crude product which precipitated was ﬁltered, washed with
water, dried and crystallized from absolute ethanol, Scheme 2.
4.3.1. Ethyl 7-methyl-3-oxo-5-phenyl-2-(2-phenylhydrazono)-
2,3-dihydro-5H-thiazolo[3,2-a]pyrimidine-6-carboxylate, 4a
m.p. 130–131 C; yield 85%; Rf. 0.41 (CHCl3:CH3COCH3
9:1); ClogP 4.95; IR (KBr) t (cm1): 1717 (ester C‚O),
1603 (C‚N); 1H NMR (CDCl3): (ppm) 1.23 (two sets, 6H,
t, CH2CH3), 2.60 (3H, s, CH3), 4.03 (two sets, 4H, q, CH2-
CH3), 6.33 (1H, s, pyr. H-5), 7.10–7.76 (11H, m, Ar–H, C2-
H), 8.83 (1H, s, NH; exchangeable with D2O). Anal. Calcd
(%) for C22H20N4O3S: C, 62.84; H, 4.79; N, 13.32. Found,
C, 62.55; H, 4.70; N, 13.39.
4.3.2. Ethyl 2-[2-(4-chlorophenyl)hydrazono]-7-methyl-3-oxo-
5-phenyl-2,3-dihydro-5H-thiazolo[3,2-a]pyrimidine-6-
carboxylate, 4b
m.p. 125–126 C; yield 62%; Rf. 0.39 (CHCl3:CH3COCH3
9:1); ClogP 5.66; IR (KBr) t (cm1): 1710 (ester C‚O),
1598 (C‚N); 1H NMR (CDCl3, 400 MHz): (ppm) 1.23 (two
sets, 6H, t, CH2CH3), 2.60 (3H, s, CH3), 4.03 (two sets, 4H,
q, CH2CH3), 6.30 (1H, s, pyr. H-5), 7.00–7.70 (11H, m, Ar–
H, C2-H), 8.13 (1H, s, NH; exchangeable with D2O). EI-MS
m/z (%) 454.95 (M+, 27), 455.95 (M++1, 38), 456.90
(M++2, 10). Anal. Calcd (%) for C22H19ClN4O3S: C, 58.08;
H, 4.21; N, 12.32. Found, C, 57.19; H, 4.62; N, 12.00.
4.3.3. Ethyl 7-methyl-2-[2-(4-methylphenyl)hydrazono]-3-oxo-
5-phenyl-2,3-dihydro-5H-thiazolo[3,2-a]pyrimidine-6-
carboxylate, 4c
m.p. 136–137 C; yield 88%; Rf. 0.45 (CHCl3:CH3COCH3
9:1); ClogP 5.45; IR (KBr) t (cm1): 1711 (ester C‚O),
1604 (C‚N); 1H NMR (CDCl3, 400 MHz): (ppm) 1.15 (two
sets, 6H, t, CH2CH3), 2.19 (3H, s, –C6H4–CH3), 2.45 (3H, s,
CH3), 3.66 (2H, q, CH2CH3), 4.04 (2H, q, CH2CH3), 6.12
(1H, s, pyr. H-5), 6.95–7.35 (11H, m, Ar–H, C2-H), 8.62
(1H, s, NH; exchangeable with D2O);
13C NMR (CDCl3):
(ppm) 13.98 (CH2CH3), 18.34 (CH2CH3), 20.69 (–C6H4–
CH3), 22.55 (7-CH3); 55.25 (C-5), 58.44 (CH2CH3), 60.63
(CH2CH3), 109.69 (C-6), 114.50 (C2-H), 120.69–139.71 (Ar–
C + Ar–CH), 151.77 (C-7), 153.36 (C-8a), 161.03 (C-3),
165.26 (ester C‚O); DEPT 13C NMR (CDCl3): d 14.00 (CH2-
CH3), 18.32 (CH2CH3), 20.73 (–C6H4–CH3), 22.59 (7-CH3),
55.25 (C-5), 58.44 (inverted CH2CH3), 60.63 (inverted CH2-
CH3), 114.52 (C-2), 128.02–132.76 (Ar–CH). Anal. Calcd
(%) for C23H22N4O3S: C, 63.58; H, 5.10; N, 12.89. Found,
C, 63.53; H, 5.09; N, 12.63.
4.4. Synthesis of ethyl 5-phenyl-3-oxo-2-isatinylidene-7-methyl-
2,3-dihydro-5H-thiazolo[3,2-a]pyrimidine-6-carboxylate,
compound, 5
To a solution of compound 3 (0.63 g, 2 mmol) in glacial acetic
acid (20 ml); isatin (0.35 g, 2.4 mmol) and fused sodium acetate
(0.57 g, 7 mmol) were added. The reaction mixture was heated
under reﬂux for 4 h, during which the product was partly
crystallized out. After cooling, the reddish compound was
ﬁltered, washed with ethanol, dried and crystallized from
ethanol, Scheme 2 5; m.p. 298–299 C; yield 62%; Rf. 0.32
Design and synthesis of some substituted thiazolo[3,2-a]pyrimidine derivatives of potential biological activities 129(CHCl3:CH3COCH3 9:1); ClogP 4.95; IR (KBr) t (cm
1):
1684 (ester C‚O), 1599 (C‚N), 3170 (NH); 1H NMR
(CDCl3, 400 MHz): (ppm) 1.26 (3 H, t, CH2CH3); 2.50 (3H,
s, CH3); 4.20 (2H, q, CH2CH3); 6.33 (1H, s, pyr. H-5); 6.83–
8.96 (9 H, m, Ar–H); 11.16 (1 H, s, NH; exchangeable with
D2O). EI-MS: m/z (%) 445 (M
+, 44), 446 (M++1, 12), 447
(M++2, 5). Anal. Calcd (%) for C22H19ClN4O3S: C, 64.71;
H, 4.30; N, 9.43. Found, C, 64.81; H, 4.45; N, 9.33.
5. Biological testing
5.1. Antimicrobial activity
5.1.1. Antibacterial activity
Compounds 2a–x, 4a–c and 5 were tested for their antibacte-
rial activity in vitro, in comparison with chloramphenicol as
a reference drug using the standard agar cup diffusion method
(Janssen and Jageneau, 1957; Sherif et al., 1993) at the Assiut
University Mycological Center (AUMC), Faculty of Science,
Assiut University, Assiut, Egypt. Five bacterial species repre-
senting both Gram-positive and Gram-negative strains which
are common contaminants of the environments in Egypt some
of which are involved in human and animal diseases were se-
lected. The used bacterial strains are S. aureus (AUMC No.
B-54) and B. cereus (AUMC No. B-5) as representatives of
Gram-positive strains, and E. coli (AUMC No. B-53), P. aeru-
ginosa (AUMC No. B-73), as well as S. marcescens (AUMC
No. B-55) as representatives of Gram-negative strains (Janssen
and Jageneau, 1957).
To prepare inocula for bioassay, bacterial strains were indi-
vidually cultured for 24 h in 100 ml conical ﬂasks containing
30 ml nutrient broth medium. Bioassay was done in 10 cm ster-
ile plastic Petri plates in which bacterial suspension (1 m/plate)
and 15 ml Nutrient agar medium (15 ml/plate) were poured.
After solidiﬁcation of the media, 5 mm diameter cavities were
cut in the solidiﬁed agar (4 cavities/plate) using sterile cork
borer. Tested compounds dissolved in dimethyl sulfoxideTable 3 Antibacterial activity of compounds (2a–x) and choramp
100 lmol/mL).
Comp No. S. aureus B. cereus
2a 8(50) 10(3.125)
2b 8(25) 12(100)
2c 8(12.5) 9(6.25)
2d 8(100) 10(0.78)
2e 8(3.125) 8(12.5)
2g 10(25) 11(25)
2i 10(50) 12(100)
2m 8(50) 10(50)
2n 8(100) –
2o 10(25) –
2s 8(25) 12(50)
2t 8(50) 12(50)
2u 10(100) –
2v 10(50) –
2w 11(100) 8(6.25)
2x 10(12.5) –
CHL 10(0.39) 12(0.19)
Pi = partial inhibition. – = no inhibition. CHL= chloramphenicol as
Center.(DMSO) at 100 lmol/ml were pipetted in the cavities (20 ll/
cavity). Cultures were then incubated at 28 ± 2 C for 48 h.
Results were taken as the diameter (in mm) of inhibition zone
around cavities and the results are cited in Table 1.
5.1.2. Antifungal activity
The synthesized compounds 2a–x, 4a–c and 5 were tested for
their antifungal activity in vitro, in comparison with clotrima-
zole as a reference drug using the standard agar cup diffusion
method (Janssen and Jageneau, 1957; Sherif et al., 1993) at the
Assiut University Mycological Center (AUMC), Faculty of
Science, Assiut University, Assiut, Egypt. Six pathogenic, phy-
togenic, or food-poisoning fungal species were used in the pres-
ent study: C. albicans (AUMC No. 418), G. candidum (AUMC
No. 226), A. ﬂavus (AUMC No. 1276), T. rubrum (AUMC No.
1804), S. brevicaulis (AUMC No. 729), and F. oxysporum
(AUMC No. 5119) (Janssen and Jageneau, 1957).
To prepare inocula for bioassay, Fungi were grown for
7 days in 100 ml conical ﬂasks containing 30 ml sabouraud’s
dextrose broth. Bioassay was done in 10 cm sterile plastic Pet-
ri plates in which fungal suspension (1 ml/plate) and 15 ml
sabouraud’s dextrose agar medium (15 ml/plate) were
poured. After solidiﬁcation of the media, 5 mm diameter
cavities were cut in the solidiﬁed agar (4 cavities/plate) using
sterile cork borer. Tested compounds dissolved in dimethyl
sulfoxide (DMSO) at 100 lmol/ml were pipetted in the
cavities (20 ll/cavity). Cultures were then incubated at
28 ± 2 C up to 7 days. Results were read as the diameter
(in mm) of inhibition zone around cavities and the results
are cited in Table 2.
5.1.3. The minimum inhibitory concentrations (MICs)
The test compounds giving positive results were diluted with
DMSO to prepare a series of descending concentrations and
were similarly assayed as mentioned before and the least con-
centration (below which no activity) was recorded as the MIC.
The results are cited in Tables 3 and 4.henicol (inhibition zone in mm and MICs given in brackets at
E. coli P. aeruginosa S. marcescens
– – –
– 13(100) –
8(6.25) 8(6.25) 10(50)
– – –
10(50) 10(50) 11(50)
8(25) 10(50) 10(50)
8(50) – –
8(50) – 16(100) p.i
12(100) 13(100) –
11(100) – –
8(25) 14(100) –
9(25) 8(50) 9(50)
10(100) 10(100) –
– – –
8(50) – –
– – –
11(1.56) 10(6.25) 14(3.125)
antibacterial standard. AUMC=Assiut University Mycological
Table 4 Antifungal activity of compounds (2a–x) and clotrimazole (inhibition zone in mm and MICs given in brackets at 100 lmol/
mL).
Comp No. C. albicans G. candidum F. oxysporum A. ﬂavus T. rubrum S. brevicaulis
2a 8(50) 8(25) 8(12.5) 8(100) 8(12.5) 12(100)
2c 8(25) 8(3.125) 10(6.25) 12(100) 8(3.125) 8(25)
2d 8(12.5) 8(3.125) 10(6.25) – 8(3.125) 16(50) p.i
2e 10(12.5) 10(6.25) 10(3.125) 13(100) 10(3.125) 8(25)
2f 10(25) – – – – –
2g 8(12.5) 8(12.5) 10(25) 14(100) 10(25) 10(25)
2h 12(100) 8(50) 8(25) – 10(50) 8(25)
2i – 10(100) 10(100) – 16(100) p.i 8(50)
2k 8(100) – – – – –
2m 14(100) 10(50) 10(50) 12(100) 10(50) 20(100)
2n – 10(12.5) 8(50) – – 14(50)
2o 13(100) 8(25) 10(100) – – 13(50)
2s 10(100) 12(12.5) 13(100) – 13(50) 16(100)
2t 10(50) 12(25) 12(25) 13(100) 8(25) 11(25)
2u 8(100) 10(12.5) 10(50) – 8(50) 23(50) p.i
2w 8(50) 8(6.25) 8(25) – 12(50) 8(50)
2x 8(25) – – – – –
CLO 12(1.56) 12(0.39) 15(0.39) 18(0.05) 10(0.05) 24(1.56) p.i
Pi = partial inhibition. – = no inhibition. CLO= clotrimazole antifungal standard. AUMC=Assiut University Mycological Center.
Table 5 Percentage of edema inhibition of compounds (2a–e, 2o, 2t–x) and indomethacin on carrageenan induced paw edema in rats.
Comp. No. Edema inhibition (%)±SE
0.5 h 1 h 2 h 3 h 4 h 5 h
Negative control – – – – – –
Indomethacin 16.07±0.29* 35.76 ± 0.00** 58.03 ± 0.17** 75.69 ± 0.29** 88.26 ± 0.17** 89.39 ± 0.17**
2a 8.15 ± 0.17*** 28.69 ± 0.17** 41.97 ± 0.29** 75.69 ± 0.29** 74.04 ± 0.17** 83.01 ± 0.17**
2b 8.15 ± 0.17*** 28.69 ± 0.17** 41.97 ± 0.17** 67.59 ± 0.00** 81.13 ± 0.17** 83.01 ± 0.17**
2c 11.99 ± 0.33* 32.12 ± 0.44** 51.64 ± 0.29** 64.83 ± 0.17** 83.40 ± 0.17** 85.06 ± 0.17**
2d 0.00 ± 0.17**** 14.35 ± 0.00* 25.91 ± 0.17** 46.03 ± 0.17** 57.44 ± 0.29** 65.90 ± 0.33**
2e 4.08 ± 0.00**** 17.99 ± 0.17** 32.30 ± 0.29** 51.38 ± 0.00** 64.54 ± 0.29** 72.28 ± 0.17**
2o 8.15 ± 0.02** 21.41 ± 0.02** 45.26 ± 0.02** 59.48 ± 0.03** 71.63 ± 0.03** 78.67 ± 0.02**
2t 4.08 ± 0.00**** 14.35 ± 0.00* 25.91 ± 0.17** 54.13 ± 0.17** 64.53 ± 0.29** 68.07 ± 0.29**
2u 4.08 ± 0.00**** 17.99 ± 0.17** 32.30 ± 0.29** 48.62 ± 0.20** 59.86 ± 0.17** 68.07 ± 0.29**
2v 16.07 ± 0.00* 35.76 ± 0.00** 58.03 ± 0.50** 67.59 ± 0.29** 78.72 ± 0.29** 87.23 ± 0.29**
2w 4.08 ± 0.00**** 17.99 ± 0.17** 32.30 ± 0.29** 48.62 ± 0.17** 64.53 ± 0.29** 65.90 ± 0.33**
2x 4.08 ± 0.00**** 17.99 ± 0.17** 32.30 ± 0.29** 46.03 ± 0.17** 59.86 ± 0.17** 68.07 ± 0.29**
* Signiﬁcant difference at p< 0.01 versus control value.
** Signiﬁcant difference at p< 0.001 versus control value.
*** Signiﬁcant difference at p< 0.05 versus control value.
**** non signiﬁcantly different at p> 0.05 versus control value (student’s test).
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5.2.1. Anti-inﬂammatory activity
Male adult albino rats (130–150 g) were obtained from the ani-
mal house, Faculty of Medicine, Assiut University, Assiut,
Egypt. Animals were housed in separate cages, 6 animals each,
in temperature-controlled rooms at 25 C. Animals were al-
lowed free access to rodent chow and water and maintained
at a 12 h light/dark cycle. Work was conducted in accordance
with the internationally accepted principles for laboratory ani-
mals’ use, care as found in the European Community Guide-
lines (Nargund et al., 1994).Indomethacin (Liometacin vial, Nile Company), Carra-
geenan (Sigma, USA), sodium carboxymethylcellulose (NaC-
MC) and normal saline were obtained from the local market.
For determination of anti-inﬂammatory activity, all tested
compounds and the reference drug were suspended in 1% so-
dium carboxymethylcellulose (NaCMC) solution in normal
saline. Suspensions of the test compounds, reference drug
and 1% (NaCMC)-saline solution (negative control) were in-
jected i.p.(1 mL each).
Compounds 2a–e, 2o and 2t–x were evaluated for their
anti-inﬂammatory activity according to the carrageenan in-
duced paw edema method (Nargund et al., 1994) in compari-
Table 6 Analgesic activity of compounds (2a–c, 2e, 2o and 2v) and aspirin using the hot-plate test.
Comp No. The average reaction time (s) at diﬀerent time intervals after compound administration ± SE
0.5 h 1 h 2 h 3 h 4 h 5 h
Control 24.00 ± 2.08 25.00 ± 1.73 22.67 ± 1.20 22.67 ± 1.20 23.33 ± 1.20 23.00 ± 1.15
Aspirin 26.33 ± 3.18* 40.00 ± 2.89** 68.00 ± 4.73** 82.67 ± 2.73** 91.67 ± 4.06** 94.00 ± 3.22**
2a 24.33 ± 2.40* 25.33 ± 2.40* 28.00 ± 2.08* 29.00 ± 1.53* 26.33 ± 1.76* 27.33 ± 1.45*
2b 24.00 ± 1.53* 28.00 ± 1.53* 29.33 ± 1.45* 31.00 ± 2.30* 31.33 ± 1.86* 31.33 ± 1.86*
2c 25.00 ± 2.08* 26.33 ± 1.86* 30.33 ± 2.91* 25.33 ± 2.96* 29.00 ± 2.08* 32.33 ± 1.76*
2e 38.00 ± 3.79*** 45.33 ± 3.18** 60.67 ± 5.61** 57.00 ± 4.73** 69.00 ± 3.51** 79.00 ± 0.58**
2o 17.00 ± 1.16* 21.00 ± 0.58* 25.33 ± 2.60* 38.33 ± 1.67** 57.00 ± 2.00** 55.33 ± 3.38**
2v 25.33 ± 2.60* 40.00 ± 2.89** 68.00 ± 2.08** 75.67 ± 2.40** 71.67 ± 4.80** 77.33 ± 3.28**
* Non signiﬁcantly different at p> 0.05 versus control value (student’s test).
** Signiﬁcantly different at p< 0.001 versus control value.
*** p< 0.01 versus control value.
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the pedal inﬂammation in rat paws induced by subplantar
injection of carrageenan suspension (0.2 mL of 1% solution
in normal saline) into the right hind of the rats. Male adult al-
bino rats were divided into groups, each of three animals. The
thickness of rat paw was measured by a Vernier caliper
(SMIEC, China) before and 1 h after carrageenan injection
to detect the carrageenan induced inﬂammation. Each tested
compound, at a dose of 54 lmol/kg, was injected i.p. to thir-
teen different groups of rats 1 h after carrageenan injection.
The control group received a vehicle (1% NaCMC solution
in normal saline), while the reference group received indometh-
acin i.p. at 54 lmol/kg.
The difference between the thicknesses of the two paws was
taken as a measure of edema. The measurement was carried
out at 0.5, 1, 2, 3, 4, and 5 h after injection of the test com-
pounds, reference drug, and control. The results are listed in
Table 5.
5.2.2. Analgesic activity
The analgesic activity of the most active anti-inﬂammatory
compounds 2a–c, 2e and 2v was evaluated in mice using the
hot plate method (Janssen and Jageneau, 1957) in comparison
to aspirin as a reference drug. In this method, the time taken
by the mouse to lick its feet or to jump within a plexiglass cyl-
inder placed on a hot plate surface (55 C) was determined.
The reaction time was taken as the end point and the increase
in hot plate latency was taken as a measure of the analgesic
activity.
All tested compounds and the reference drug were sus-
pended in 1% sodium carboxymethylcellulose (NaCMC)
saline solution. Suspensions of the tested compounds, refer-
ence drug and 1% sodium carboxymethylcellulose (NaC-
MC) saline solution (negative control) were injected
i.p.(1 mL each).
Male adult albino mice (25–30 g) were divided into eight
groups, each of three animals. Solutions or suspensions of
the test compounds and the reference drug in 1% sodium car-
boxymethylcellulose (NaCMC) solution were injected i.p. in a
dose level of 300 lmol/kg into mice. The control group of ani-
mals was similarly treated with 1% sodium carboxymethylcel-
lulose (NaCMC) saline solution. The reaction time was
evaluated directly 0.5, 1, 2, 3, 4 and 5 h of ﬁrst injection.
The results are cited in Table 6.5.2.3. Acute toxicity (LD50)
The median lethal dose (LD50) of the most active anti-inﬂam-
matory and analgesic compounds 2e and 2v was determined in
mice.
Groups of male adult albino mice, each of three animals
(25–30 g), were injected i.p. with graded doses of the test
compounds. The percentage mortality in each group of
animals was determined 24 h later to the injection (Sztaricskai
et al., 1999).
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